The Experts below are selected from a list of 324 Experts worldwide ranked by ideXlab platform
Karin Sundfeldt - One of the best experts on this subject based on the ideXlab platform.
-
diagnostic potential of tumor dna from Ovarian Cyst fluid
eLife, 2016Co-Authors: Yuxuan Wang, Karin Sundfeldt, Constantina Mateoiu, Ie Ming Shih, Robert J Kurman, Joy Schaefer, Natalie Silliman, Isaac Kinde, Simeon Springer, Michael FooteAbstract:More than a third of women develop Ovarian Cysts during their lifetimes. The vast majority of these Cysts are harmless, but a small number are caused by Ovarian cancers. These cancers often produce no symptoms until the disease has spread throughout the abdomen or to other organs, so many women go undiagnosed until their chances of being successfully treated are low. Currently, there is no reliable way to determine whether an Ovarian Cyst is cancerous without performing surgery. As a result, many women undergo unnecessary, invasive surgeries for harmless Ovarian Cysts. Tumors shed cells and cell fragments into any fluid that surrounds them. Fluids from Cysts in the pancreas, kidney, and thyroid are routinely examined to identify whether they contain cancerous cells. Now, Wang, Sundfeldt et al. show that Ovarian cancers also shed DNA into the surrounding Cyst fluid. Furthermore, mutations found in this DNA can provide valuable information about whether the Cysts are cancerous. The study was performed by extracting DNA from the fluid in Ovarian Cysts that had been surgically removed from 77 women. Of these Cysts, 10 were harmless Cysts, 12 were benign tumors, 31 were invasive cancers, and 24 were so-called borderline tumors, which fall somewhere between the benign tumors and invasive cancers. Only Cysts associated with the borderline tumors and invasive cancers need to be surgically removed. Here, Wang, Sundfeldt et al. report that DNA mutations that are characteristic of Ovarian cancers were found in 87% of the Cysts associated with borderline tumors and invasive cancers. In contrast, these mutations were not found in any of the Cysts that do not require surgery. Fluid can be extracted from an Ovarian Cyst with a needle during an outpatient visit. Therefore, the results presented by Wang, Sundfeldt et al. suggest a relatively straightforward way of testing the DNA from Ovarian Cysts before deciding whether surgery is really necessary. First, however, larger studies that follow women with Cysts over time will be necessary to confirm that this type of testing is effective and safe.
-
potential tumor biomarkers identified in Ovarian Cyst fluid by quantitative proteomic analysis itraq
Clinical Proteomics, 2013Co-Authors: Bjorg Kristjansdottir, Kristina Levan, Karolina Partheen, Elisabet Carlsohn, Karin SundfeldtAbstract:Background Epithelial-derived Ovarian adenocarcinoma (EOC) is the most deadly gynecologic tumor, and the principle cause of the poor survival rate is diagnosis at a late stage. Screening and diagnostic biomarkers with acceptable specificity and sensitivity are lacking. Ovarian Cyst fluid should harbor early Ovarian cancer biomarkers because of its closeness to the tumor. We investigated Ovarian Cyst fluid as a source for discovering biomarkers for use in the diagnosis of EOC.
-
Potential tumor biomarkers identified in Ovarian Cyst fluid by quantitative proteomic analysis, iTRAQ
Clinical Proteomics, 2013Co-Authors: Bjorg Kristjansdottir, Kristina Levan, Karolina Partheen, Elisabet Carlsohn, Karin SundfeldtAbstract:Background Epithelial-derived Ovarian adenocarcinoma (EOC) is the most deadly gynecologic tumor, and the principle cause of the poor survival rate is diagnosis at a late stage. Screening and diagnostic biomarkers with acceptable specificity and sensitivity are lacking. Ovarian Cyst fluid should harbor early Ovarian cancer biomarkers because of its closeness to the tumor. We investigated Ovarian Cyst fluid as a source for discovering biomarkers for use in the diagnosis of EOC. Results Using quantitative mass spectrometry, iTRAQ MS, we identified 837 proteins in Cyst fluid from benign, EOC stage I, and EOC stage III. Only patients of serous histology were included in the study. Comparing the benign (n = 5) with the malignant (n = 10) group, 87 of the proteins were significantly (p
-
Ovarian Cyst fluid is a rich proteome resource for detection of new tumor biomarkers
Clinical Proteomics, 2012Co-Authors: Bjorg Kristjansdottir, Eric T Fung, Karolina Partheen, Janusz Marcickiewicz, Mats Brannstrom, Karin SundfeldtAbstract:Background We aimed to investigate the use of Ovarian Cyst fluid as a source for biomarker discovery and to find novel biomarkers for use in the diagnosis of epithelial Ovarian tumors.
Giovanni Scambia - One of the best experts on this subject based on the ideXlab platform.
-
telelap alf x assisted laparoscopy for Ovarian Cyst enucleation report of the first 10 cases
Journal of Minimally Invasive Gynecology, 2015Co-Authors: Salvatore Gueli Alletti, Cristiano Rossitto, Francesco Fanfani, Anna Fagotti, Barbara Costantini, Stefano Gidaro, Giorgia Monterossi, Luigi Selvaggi, Giovanni ScambiaAbstract:Abstract This prospective single-institutional clinical trial sought to assess the safety and feasibility of laparoscopic benign Ovarian Cyst enucleation with a novel robotic-assisted laparoscopic system. Here we report a series of 10 patients treated using the Telelap ALF-X system in the first clinical application on patients at the Division of Gynecologic Oncology, Catholic University of the Sacred Heart of Rome. The primary inclusion criterion was the presence of monolateral Ovarian Cyst without a preoperative assessment suspicious for malignancy. Intraoperative data, including docking time, operative time, estimated blood loss, intraoperative and perioperative complications, and conversion to either standard laparoscopy or laparotomy, were collected. The Cysts were removed with an ovary-sparing technique with respect to conservative surgical principles. The median operative time was 46.3 minutes, and patients without postoperative complications were discharged at 1 or 2 days after the procedure. Telelap ALF-X laparoscopic enucleation of benign Ovarian Cysts with an ovary-sparing technique is feasible, safe, and effective; however, more clinical data are needed to determine whether this approach can offer any other benefits over other minimally invasive surgical techniques.
-
laparoendoscopic single site surgery less for Ovarian Cyst enucleation report of first 3 cases
Fertility and Sterility, 2009Co-Authors: Anna Fagotti, Cristiano Rossitto, Francesco Fanfani, Francesco Marocco, Valerio Gallotta, Giovanni ScambiaAbstract:Objective To report the feasibility of Ovarian Cyst enucleation by using a laparoendoscopic single-site trocar through a transumbilical access. Design Case reports. Setting Teaching and research hospital. Patient(s) Three patients affected by large Ovarian Cysts. Intervention(s) Enucleation of three large Ovarian Cysts by using a laparoendoscopic single-site approach with a new multiport trocar and standard laparoscopic instruments. Main Outcome Measure(s) Conversion to a multiaccess standard laparoscopic technique. Result(s) No conversion to multiaccess standard laparoscopic technique and no intraoperative or postoperative complications were observed. Mean operative time was 79.6 minutes. All patients were discharged home on day 1. Conclusion(s) Laparoendoscopic single-site enucleation of large Ovarian Cysts with ovary sparing is feasible with standard laparoscopic instruments, safe and effective, with good results in terms of cosmesis and postoperative pain. More clinical data are needed to confirm these advantages compared with standard laparoscopic technique.
Bjorg Kristjansdottir - One of the best experts on this subject based on the ideXlab platform.
-
potential tumor biomarkers identified in Ovarian Cyst fluid by quantitative proteomic analysis itraq
Clinical Proteomics, 2013Co-Authors: Bjorg Kristjansdottir, Kristina Levan, Karolina Partheen, Elisabet Carlsohn, Karin SundfeldtAbstract:Background Epithelial-derived Ovarian adenocarcinoma (EOC) is the most deadly gynecologic tumor, and the principle cause of the poor survival rate is diagnosis at a late stage. Screening and diagnostic biomarkers with acceptable specificity and sensitivity are lacking. Ovarian Cyst fluid should harbor early Ovarian cancer biomarkers because of its closeness to the tumor. We investigated Ovarian Cyst fluid as a source for discovering biomarkers for use in the diagnosis of EOC.
-
Potential tumor biomarkers identified in Ovarian Cyst fluid by quantitative proteomic analysis, iTRAQ
Clinical Proteomics, 2013Co-Authors: Bjorg Kristjansdottir, Kristina Levan, Karolina Partheen, Elisabet Carlsohn, Karin SundfeldtAbstract:Background Epithelial-derived Ovarian adenocarcinoma (EOC) is the most deadly gynecologic tumor, and the principle cause of the poor survival rate is diagnosis at a late stage. Screening and diagnostic biomarkers with acceptable specificity and sensitivity are lacking. Ovarian Cyst fluid should harbor early Ovarian cancer biomarkers because of its closeness to the tumor. We investigated Ovarian Cyst fluid as a source for discovering biomarkers for use in the diagnosis of EOC. Results Using quantitative mass spectrometry, iTRAQ MS, we identified 837 proteins in Cyst fluid from benign, EOC stage I, and EOC stage III. Only patients of serous histology were included in the study. Comparing the benign (n = 5) with the malignant (n = 10) group, 87 of the proteins were significantly (p
-
Ovarian Cyst fluid is a rich proteome resource for detection of new tumor biomarkers
Clinical Proteomics, 2012Co-Authors: Bjorg Kristjansdottir, Eric T Fung, Karolina Partheen, Janusz Marcickiewicz, Mats Brannstrom, Karin SundfeldtAbstract:Background We aimed to investigate the use of Ovarian Cyst fluid as a source for biomarker discovery and to find novel biomarkers for use in the diagnosis of epithelial Ovarian tumors.
Saeed Alborzi - One of the best experts on this subject based on the ideXlab platform.
-
a comparison of histopathologic findings of Ovarian tissue inadvertently excised with endometrioma and other kinds of benign Ovarian Cyst in patients undergoing laparoscopy versus laparotomy
Fertility and Sterility, 2009Co-Authors: Perikala V Kumar, Leila Foroughinia, Nasrin Asadi, Saeed AlborziAbstract:OBJECTIVE: To evaluate Ovarian tissue inadvertently excised with benign Cysts during laparotomy or laparoscopy. DESIGN: Prospective study. SETTING: Private and university hospitals. PATIENT(S): 260 women, 20 to 35 years old, with unilateral benign Ovarian Cysts. INTERVENTION(S): One hundred fifty women operated by laparoscopic Cystectomy stripping technique, and 110 women operated by laparotomy with the same technique. MAIN OUTCOME MEASURE(S): Histopathologic findings of Ovarian tissue inadvertently excised in endometrioma compared with other kinds of benign Cysts in laparoscopy versus laparotomy. RESULT(S): In the laparoscopy group, Ovarian tissue was present in 65% of endometrioma and in 32% of nonendometriotic Cysts. In the laparotomy group, Ovarian tissue was seen in 80% of endometrioma and 41% of nonendometriotic Cysts. CONCLUSION(S): The surgical approach had no statistically significant impact on conservation of Ovarian reserves. The nature of the Ovarian Cyst played a greater role in the quality and quantity of the excised Ovarian tissue.
Anna Fagotti - One of the best experts on this subject based on the ideXlab platform.
-
telelap alf x assisted laparoscopy for Ovarian Cyst enucleation report of the first 10 cases
Journal of Minimally Invasive Gynecology, 2015Co-Authors: Salvatore Gueli Alletti, Cristiano Rossitto, Francesco Fanfani, Anna Fagotti, Barbara Costantini, Stefano Gidaro, Giorgia Monterossi, Luigi Selvaggi, Giovanni ScambiaAbstract:Abstract This prospective single-institutional clinical trial sought to assess the safety and feasibility of laparoscopic benign Ovarian Cyst enucleation with a novel robotic-assisted laparoscopic system. Here we report a series of 10 patients treated using the Telelap ALF-X system in the first clinical application on patients at the Division of Gynecologic Oncology, Catholic University of the Sacred Heart of Rome. The primary inclusion criterion was the presence of monolateral Ovarian Cyst without a preoperative assessment suspicious for malignancy. Intraoperative data, including docking time, operative time, estimated blood loss, intraoperative and perioperative complications, and conversion to either standard laparoscopy or laparotomy, were collected. The Cysts were removed with an ovary-sparing technique with respect to conservative surgical principles. The median operative time was 46.3 minutes, and patients without postoperative complications were discharged at 1 or 2 days after the procedure. Telelap ALF-X laparoscopic enucleation of benign Ovarian Cysts with an ovary-sparing technique is feasible, safe, and effective; however, more clinical data are needed to determine whether this approach can offer any other benefits over other minimally invasive surgical techniques.
-
laparoendoscopic single site surgery less for Ovarian Cyst enucleation report of first 3 cases
Fertility and Sterility, 2009Co-Authors: Anna Fagotti, Cristiano Rossitto, Francesco Fanfani, Francesco Marocco, Valerio Gallotta, Giovanni ScambiaAbstract:Objective To report the feasibility of Ovarian Cyst enucleation by using a laparoendoscopic single-site trocar through a transumbilical access. Design Case reports. Setting Teaching and research hospital. Patient(s) Three patients affected by large Ovarian Cysts. Intervention(s) Enucleation of three large Ovarian Cysts by using a laparoendoscopic single-site approach with a new multiport trocar and standard laparoscopic instruments. Main Outcome Measure(s) Conversion to a multiaccess standard laparoscopic technique. Result(s) No conversion to multiaccess standard laparoscopic technique and no intraoperative or postoperative complications were observed. Mean operative time was 79.6 minutes. All patients were discharged home on day 1. Conclusion(s) Laparoendoscopic single-site enucleation of large Ovarian Cysts with ovary sparing is feasible with standard laparoscopic instruments, safe and effective, with good results in terms of cosmesis and postoperative pain. More clinical data are needed to confirm these advantages compared with standard laparoscopic technique.